Clinical Trial of Recombinant Pneumococcal Protein Vaccine

Randomized, Blinded, Positive-controlled Phase Ib Clinical Trial for Preliminary Evaluation of Safety and Immunogenicity of Recombinant Pneumococcal Protein Vaccine in Adults Aged 50 Years and Older After Vaccination

Streptococcus pneumoniae infections often cause serious health problems, especially in infants and the elderly. Failure to cover all polysaccharide types of vaccines is a greater problem for adults than for children.

The purpose of this study was to preliminarily evaluate the safety and immunogenicity of a recombinant pneumococcal protein vaccine applied to adults aged 50 years and older to provide a basis for subsequent clinical trial design.

Study Overview

• Status: Active, not recruiting
• Conditions: Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia
• Intervention / Treatment: Biological: PBPV; Biological: PPV23

Detailed Description

The risk of Streptococcus pneumoniae infection varies widely with age, underlying disease, and living environment. Worldwide, infants and the elderly are at high risk for pneumococcal disease. Disease from pneumococcal infections can affect multiple organ systems and lead to multiple disease syndromes. This vaccine has a higher coverage rate, capable of reaching more than 94%. With the high coverage rate, it can effectively prevent the occurrence of serotype substitution and the outbreak of antibiotic-resistant pneumococcal-associated diseases.

This clinical trial is a Phase Ib clinical trial in adults aged 50 years and older based on the Phase Ia clinical trial.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Chunquan Wang; Phone Number: 13769933139; Email: lccdczxb@163.com
• Study Contact Backup: Name: Yan Zheng, Associate Chief Physician; Phone Number: 18987115640; Email: yaqueer_zy@163.com

Study Locations

• China
  • Yunnan
    • Puer, Yunnan, China
      • Lancang Lahu Autonomous County Center for Disease Control and Prevention
      • Contact: Chunquan Wang; Phone Number: 13769933139; Email: lccdczxb@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 48 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Adults 50 years and older at the time of screening
• Willingness to provide legal proof of identity
• Ability to understand the clinical study and voluntarily sign an informed consent form and complete a 6-month follow-up
• Ability to comply with the requirements of the clinical research protocol

Exclusion Criteria:

• Fever, axillary body temperature >37.0℃ before vaccination
• Positive human immunodeficiency virus (HIV) screening
• History of epilepsy, convulsions or seizures or a history of psychiatric illness or family history
• Received immunosuppressive therapy, cytotoxic therapy, glucocorticoid therapy (excluding topical therapy, surface therapy for acute uncomplicated dermatitis, spray therapy for allergic rhinitis) within the past 6 months (interval <6 months)
• Suffering from serious chronic diseases or conditions in progress that can't be controlled smoothly, such as serious cardiovascular diseases, chronic hemolytic anemia, thyroid diseases, etc. (except thyroid nodules)
• History of severe anaphylactic reactions (e.g., systemic allergic reactions) to any component of the test drug and/or history of serious adverse reactions associated with other vaccines, such as allergy, urticaria, dyspnea, angioneurotic edema, or abdominal pain
• People with hypertension that cannot be controlled by medication (when measured on site: systolic blood pressure ≥ 160 mmHg, diastolic blood pressure is ≥ 100 mmHg)
• Pre-immune hemoglobin, white blood cell count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatine phosphokinase (CPK), and troponin (CTN) test results are abnormal and are judged by the investigator to be clinically significant
• Positive urine pregnancy test or lactating women, volunteers or their partners planning to become pregnant
• Diseases caused by Streptococcus pneumoniae such as pneumococcal pneumonia, pneumococcal meningitis, etc. within the last 5 years
• Allergic persons, such as those who are allergic to two or more drugs or foods or those who are severely allergic to one drug or food
• Immunocompromised individuals with known or suspected congenital/acquired immunodeficiency as determined by medical history and/or physical examination, uncontrolled autoimmune diseases, etc
• Abnormal coagulation (e.g., clotting factor deficiency, coagulopathy, platelet abnormalities) or significant bruising or clotting disorders
• No spleen or splenectomy due to any condition
• Acute attack of various acute or chronic diseases within the last 7 days
• Pneumococcal vaccination within the last 5 years
• Received or planned to receive blood/plasma products or immunoglobulins during the study period or 3 months prior to vaccination
• Received or plan to participate in an interventional study, receive another investigational drug, vaccine or treatment during the study within the last 1 month
• Received live attenuated vaccine within the last 14 days
• Received subunit vaccine or inactivated vaccine within the last 7 days
• Those planning to have surgery during the study period
• Subject has any other factors that, in the judgment of the investigator, make them unsuitable for participation in the clinical trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Recombinant Pneumococcal Protein Vaccine（PBPV）; Subjects received 1 dose of PBPV	Biological: PBPV; Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
Active Comparator: Pneumococcal Polysaccharide Vaccine-23-valent (PPV23); Subjects received 1 dose of PPV23	Biological: PPV23; Intramuscular injection, 1 dose of 0.5ml inoculated on day 0

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of adverse reactions 0~7 days after vaccination	0~7 days after vaccination
Incidence of adverse reactions 0~30 days after vaccination	0~30 days after vaccination
Positive (4-fold change) rate of serum Pneumococcal surface protein A(PspA)-RX1, PspA-3296, PspA-5668 and PlyLD protein antibodies at day 30, 3 months and 6 months after vaccination	Day 30, 3 months and 6 months after vaccination

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of adverse reactions within 30 minutes after vaccination	30 minutes after vaccination
Incidence of adverse events within 30 days after vaccination	30 days after vaccination
Incidence of Serious Adverse Event (SAE) within 6 months after vaccination	6 months after vaccination
Evaluation of the incidence of abnormal laboratory hematology values, including hemoglobin, white blood cell count, alanine aminotransferase (AT), aspartate AT, total bilirubin, creatine phosphokinase , before and on day 8 of the subject's exemption	Before and on day 8 of the subject's exemption
Serum PspA-RX1, PspA-3296, PspA-5668, PlyLD protein antibody Geometric Mean Titer (GMT) at 30 days, 3 months and 6 months before and after vaccination	30 days, 3 months and 6 months before and after vaccination
Serum PspA-RX1, PspA-3296, PspA-5668, PlyLD protein antibody Geometric Mean Increase (GMI) at 30 days, 3 months and 6 months before and after vaccination	30 days, 3 months and 6 months before and after vaccination
Serum Ply antibody neutralization test activity at 30 days, 3 months and 6 months before and after vaccination	30 days, 3 months and 6 months before and after vaccination
GMT of serotype specific Multiplexed Opsonophagocytic Killing Assay (MOPA) at 30 days, 3 months and 6 months before and after vaccination	30 days, 3 months and 6 months before and after vaccination
Positive conversion rate of serotype specific Multiplexed Opsonophagocytic Killing Assay (MOPA) at 30 days, 3 months and 6 months before and after vaccination	30 days, 3 months and 6 months before and after vaccination
GMI of serotype specific Multiplexed Opsonophagocytic Killing Assay (MOPA) at 30 days, 3 months and 6 months before and after vaccination	30 days, 3 months and 6 months before and after vaccination

Collaborators and Investigators

• Sponsor: CanSino Biologics Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2023
• Primary Completion (Estimated): December 11, 2023
• Study Completion (Estimated): December 11, 2023

Study Registration Dates

• First Submitted: November 3, 2022
• First Submitted That Met QC Criteria: November 10, 2022
• First Posted (Actual): November 21, 2022

Study Record Updates

• Last Update Posted (Actual): October 23, 2023
• Last Update Submitted That Met QC Criteria: October 19, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: Safety; Vaccine; Immunogenicity; PspA; Pneumolysin; >=50 years
• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases
• Other Study ID Numbers: CTP-PBPV-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: In order to maintain the rights of the subject, do not open the Individual Participant Data (IPD)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No